N
NovaBridge Biosciences (NBP)
NGM – Real Time Price. Currency in USD
2.06
-0.04 (-1.90%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
2.06
-0.04 (-1.90%)
At close: May 12, 2026, 4:00 PM EDT
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-04-22 | 6-K | mark_hagler_pr_-_04-22-2.htm |
| 2026-04-07 | 20-F | nbp-20251231.htm |
| 2026-03-16 | 6-K | giva_fda_pr_-_03-16-26.htm |
| 2026-03-09 | 6-K | vis-101_pr_and_decks_-_0.htm |
| 2026-03-03 | 6-K | visara_cr_pr_-_03-03-26.htm |
| 2026-02-25 | 6-K | updated_ir_deck_-_02-25-.htm |
| 2026-02-19 | 6-K | cunningham_pr_2-19-26.htm |
| 2026-02-17 | 6-K | giva_ph_2_fpi_pr_-_02-17.htm |
| 2026-02-06 | 6-K/A | ir_deck_update_-_2-6-26_.htm |
| 2026-02-06 | 6-K | updated_ir_deck_-_02-06-.htm |